Woburn biotech to Lay Off Over 200 Employees After FDA Treatment Rejection
SOURCENews reportView the filing ↗
What we know
Location: Woburn, MA.
Based on news reporting.
Summary
Company, a biotech firm based in Woburn, is set to lay off more than 200 employees following a second rejection from the FDA regarding its skin cancer treatment. The decision comes as the company faces significant challenges in bringing its product to market, which has led to a reevaluation of its workforce needs. The layoffs are a direct response to the setbacks in regulatory approval and are part of a broader strategy to streamline operations. This move underscores the difficulties faced by biotech companies in navigating the complex landscape of drug approval processes.
Replimune cut 200 jobs in MA as of April 17, 2026.
LayoffTalk has tracked 3 layoff events at Replimune since April 2026, including 224 jobs documented in official WARN filings, with 1 additional event known from news reporting.
Comments (0)
Anonymous by default. Be kind — people reading this may be going through it right now.
No comments yet. Be the first to share your thoughts.
Affected by this?
Share your story anonymously — it helps others reading this feel less alone.
Share your story →More layoffs at Replimune
Recent tracked events at this company.
Recent layoffs in MA
Other companies with tracked events in the same state.